Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Drug Discov Today. 2020 Oct 16;26(1):189–199. doi: 10.1016/j.drudis.2020.10.006

Figure 1.

Figure 1.

(a) A general schematic diagram for homobivalent and heterobivalent ligands. (b) The chemical structures of the bivalent ligand KDN21 and its two monomeric counterparts, NTI and GNTI. (c) The chemical structures of the bivalent ligand MCC22 and the two lead compounds oxymorphone and TAK-220.